Break free from nucleases

A year after being spun out from 5AM Ventures’ incubator, Homology Medicines Inc. is showing the first fruits of its $43.5 million series A round with efficacy data on its gene editing adeno-associated viral (AAV) vector platform.

At the American Society of Gene & Cell Therapy (ASGCT) meeting in Washington, D.C. last month, Homology presented data on its AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) platform, highlighting the mechanism, high efficiency and low off-target activity of its gene editing vectors...